'Was drawn to science from class VII': Tamil Nadu daily wagers' daughter with dwarfism set to join IIT-Bombay
VIRUDHUNAGAR: A few years ago, S Yogeshwari had no idea what aerospace engineering was. Today, the girl with disabilities from rural Virudhunagar is set to join
IIT Bombay
to study it, a journey powered by hard work, perseverance, and support from her family, teachers, and govt schemes.
Yogeshwari's mother, Kanagavalli, works as a daily wage labourer in a fireworks unit, while her father, Selvam, is employed at a tea shop.
A Class XII graduate from Padanthal Govt Higher Secondary School near Sattur, Yogeshwari said, 'My parents always encouraged me and my two elder brothers to pursue education. I was drawn to science from ClassVII, initially leaning towards medical science.
In Class XII, I discovered aerospace engineering through programmes like the Naan Mudhalvan scheme in school.'
Inspired by her brothers — one studying BCom, the otherphysical education — she decided to take the JEE Mains after Class XII.
'I scolded her at first for scoring below 450 marks when she expected more, but she challenged me that she'd do well in JEE. And she did — my tears of anger turned into tears of pride,' said her mother.
Yogeshwari, who has dwarfism, attended a 40-day residential JEE Advanced coaching camp in Erode, despite her parents' initial worries. 'Coming from a Tamilmedium background, JEE Advanced was tough at first. But with my teachers' help, I cleared it,' she said.
Virudhunagar collector V P Jeyaseelan has assured her full support as she prepares to join IIT Bombay.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
2 hours ago
- Indian Express
Hope for stomach, brain cancer? Cancer-fighting immune therapy works on solid tumours in early trials
Despite a failed bone marrow transplant, Delhi's Dr (Col) VK Gupta beat his blood cancer after receiving CAR T-cell therapy at Tata Memorial Hospital. Not only did he recover, he was able to go back to work in his outpatient clinic. He is among those with blood cancer who has benefitted from this cutting edge cancer treatment that re-engineers the body's own immune cells, enabling them to fight the cancerous ones. Can this therapy now work for solid and hard-to-treat tumours as well? Earlier this month, there was good news on this front with two studies indicating increase in life span. Positive results from the first ever phase II trial of CAR T-cell therapy for solid cancers — those in the form of gastrointestinal tumours — were published from China. Another early study on the impact of a double target CAR T-cell therapy on a very difficult-to-treat brain cancer was also published in the US. 'With so many people working on the problem, it is possible that we could soon see CAR T-cell therapy for solid cancers. While the results are unlikely to be as dramatic as we have seen with blood cancers, any hope is good when survival otherwise is just a couple of months,' says Dr Hasmukh Jain, a specialist of blood cancers from Tata Memorial Hospital. He collaborated with the IIT Bombay team that developed the country's first CAR T-cell therapy. CAR T-cell therapy essentially uses a cancer patient's own immune T-cells and engineers them in a laboratory to add receptors that can bind specifically with the cancer cells only. These engineered cells are then multiplied and infused in the patient. Usually, the cancerous cells have the ability to hide from the unmodified T-cells. However, with the new receptors on the T-cells, they cannot. The body's immune system then kills the cancer cells. This, experts say, is because it is much more difficult to target solid cancers than blood cancers. 'One of the biggest problems with CAR T-cell therapy for solid cancers is that there aren't enough good targets. Several of the solid cancer markers are also found on normal, healthy cells, so they cannot be used. There have been cases of pulmonary toxicity with therapies whose target was expressed in small quantities in the lungs. Or, take for example, the BRCA gene mutations in breast cancers; these are expressed by other healthy cells as well,' says Dr Mayank Singh, associate professor of medical oncology at AIIMS-New Delhi. Another challenge is that the same type of cancer may be molecularly very different in different patients — or even within the same patient — making it extremely difficult to find a suitable target for CAR T. Besides, solid tumours are a more complex disease, says Dr Jain. 'Unlike blood cancers, other cancers are not in the blood where the T-cells are. So, they have to find the tumour and enter it. This is difficult as the T- cells are not able to effectively penetrate the tumour microenvironment or the immediate area round the tumour,' he explains. This is hostile towards immune cells and can deactivate them, including the modified T-cells given to patients. The phase II study from China showed that the outcome was better with the new CAR T therapy as compared to the therapy generally prescribed by the physician. Patients with gastrointestinal cancers carrying a specific mutation called CLDN18.2 — having received two unsuccessful treatments previously — were given either the new therapy or existing treatments. The study found that 35 per cent of the patients given the new treatment responded as compared to 4 per cent of those on existing treatments. Those on the new therapy also lived 2.4 months longer on average as compared to the control group. Another new CAR T-cell therapy, which used two targets instead for a very difficult to treat brain tumour called glioblastoma, showed promise in a trial conducted at University of Pennsylvania. The tumours became smaller in nearly two-thirds of the patients with recurrent glioblastoma who received the novel therapy. And, several of the patients have already lived 12 months or longer, which is significant considering that people with this type of cancer typically survive only for six to ten months. Importantly, the researchers also found evidence to suggest that the modified T-cells remained in the patients' immune system and continued to prevent tumour growth over time. Experts say that studies on brain and spinal cancers called gliomas and those targeting CLDN18.2 are probably at the most advanced stages of development and may be approved within a few years. 'Now, researchers are using AI to identify suitable targets for CAR T therapies. This is the reason for the recent increase in trials,' says Dr Singh. The IIT Bombay-incubated start-up ImmunoACT is also working on a therapy that can work on brain and nerve cell cancers called glioblastoma and neuroblastoma. Another therapy that it is pursuing will work on the gastric and gastroesophageal junction cancers — the same cancers as the Chinese trial looked at. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
Time of India
4 hours ago
- Time of India
'Was drawn to science from class VII': Tamil Nadu daily wagers' daughter with dwarfism set to join IIT-Bombay
VIRUDHUNAGAR: A few years ago, S Yogeshwari had no idea what aerospace engineering was. Today, the girl with disabilities from rural Virudhunagar is set to join IIT Bombay to study it, a journey powered by hard work, perseverance, and support from her family, teachers, and govt schemes. Yogeshwari's mother, Kanagavalli, works as a daily wage labourer in a fireworks unit, while her father, Selvam, is employed at a tea shop. A Class XII graduate from Padanthal Govt Higher Secondary School near Sattur, Yogeshwari said, 'My parents always encouraged me and my two elder brothers to pursue education. I was drawn to science from ClassVII, initially leaning towards medical science. In Class XII, I discovered aerospace engineering through programmes like the Naan Mudhalvan scheme in school.' Inspired by her brothers — one studying BCom, the otherphysical education — she decided to take the JEE Mains after Class XII. 'I scolded her at first for scoring below 450 marks when she expected more, but she challenged me that she'd do well in JEE. And she did — my tears of anger turned into tears of pride,' said her mother. Yogeshwari, who has dwarfism, attended a 40-day residential JEE Advanced coaching camp in Erode, despite her parents' initial worries. 'Coming from a Tamilmedium background, JEE Advanced was tough at first. But with my teachers' help, I cleared it,' she said. Virudhunagar collector V P Jeyaseelan has assured her full support as she prepares to join IIT Bombay.
Hindustan Times
6 hours ago
- Hindustan Times
22 from state score 100 percentile in MHT-CET for engg
MUMBAI: Twenty two students from the state have scored a perfect 100 percentile in the Maharashtra Technical Common Entrance Test (MHT-CET) for engineering and agriculture undergraduate courses, whose results were declared on Monday. However, the number has dropped compared to last year, when 37 students achieved the top percentile. Of the 22 students who topped the exam, 14 are already on track to secure admission into various Indian Institutes of Technology (IITs). Four of the top scorers are from outside Maharashtra, while another four plan to use their CET scores to gain admission to engineering colleges within the state. The MHT-CET exam for the Physics, Chemistry, and Mathematics (PCM) group was conducted across 28 sessions, between April 19 and May 5. Of the 4,64,263 students who registered for the PCM group, 4,22,863 took the exam. The Physics, Chemistry, and Biology (PCB) group examination was held from April 22 to 30. Of the 3,14,675 registered students, 2,95,577 took the test. The results of the PCB group will be declared on Tuesday. Many of the CET toppers also performed exceptionally well in the JEE Advanced examination, conducted for admission to undergraduate programmes in the IITs and NITs. Siddhant Ghate from Powai, who secured 100 percentile in the CET, said that preparing for the JEE Advanced exam made the CET relatively easy. 'I focused on a higher level of preparation for the JEE. That helped me clear both the JEE Mains and CET smoothly,' he said. Ghate secured an All-India Rank (AIR) of 243 in the JEE Advanced exam and is aiming for admission to IIT Kanpur for computer science engineering. Anirudh Iyer from Chembur also scored 100 percentile in the CET and ranked 198 in the JEE Advanced. A former student of Somaiya School, Iyer said, 'My interest lies in physics and I want to pursue research. I'm trying to get into IIT-Bombay or IISc for physics.' Among the top scorers from Mumbai and Thane are Pranav Mintri, Vipul Meer and Arnav Nigam. Mintri, who achieved AIR 141 in JEE Advanced, is seeking admission to IIT-Bombay. Meer, a student of Cathedral School in Mumbai, secured AIR 69 and hopes to join IIT-Delhi. Arnav Nigam, who lives in Goregaon and studied at Vibgyor High School, secured AIR 11 in JEE Advanced. In addition to his top rank, he has qualified for several national science Olympiads and is looking forward to pursuing computer science at IIT-Bombay. While the results were being celebrated across the state, a few parents raised concerns about the percentile calculation method used in this year's CET results. The State Common Entrance Test Cell is yet to respond to these concerns.
